Pulmatrix Announces Cross License Agreement and Transfer of Laboratory to MannKind Corporation

Cross license involves Pulmatrix iSPERSE™ technology and MannKind's Cricket® inhalation device. Pulmatrix transferring leased building, all leasehold improvements, laboratory equipment and other related personal property in exchange for MannKind assumption of lease. For more on the Company's inhaled product candidates please visit: https://www.pulmatrix.com/pipeline.html. About PUR3100 PUR3100 is an orally inhaled formulation of dihydroergotamine (DHE) engineered with iSPERSE™ for the treatment of acute mig ...